United States — Food and Drug Administration & United States — National Cancer Institute

United States — Food and Drug Administration: The FDA will review the trial data for potential approval. The companies plan to file for approval, and the vaccine could be available as soon as 2027 if approved.

United States — National Cancer Institute: The NCI has funded cancer vaccine trials, including mRNA-based ones, and its support is noted in the context of the research.

United States — Food and Drug Administration: The United States — Food and Drug Administration>>> granted Priority Review for Roche>>>'s Atezolizumab, indicating a potential new treatment option for colon cancer patients.

United States — National Cancer Institute: The United States — National Cancer Institute>>> sponsored the ATOMIC study, which provided the data for Roche>>>'s sBLA filing.

United States — Food and Drug Administration: The FDA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the FDA.

United States — National Cancer Institute: NCI is a research partner of Ascentage Pharma, but this event does not directly involve NCI.

United States — National Cancer Institute: The United States — National Cancer Institute is sponsoring trials for iadademstat in various hematologic malignancies and solid tumors under a Cooperative Research and Development Agreement with Oryzon Genomics.

United States — National Cancer Institute: The United States — National Cancer Institute is where Dr. Steven Rosenberg has served as Chief of the Surgery Branch since 1974, providing the institutional support for his foundational work in cancer immunotherapy.

United States — National Cancer Institute: The United States — National Cancer Institute partially funded the study, supporting critical cancer research.